絞り込み

16532

広告

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).

著者 Drgona L , Gudiol C , Lanini S , Salzberger B , Ippolito G , Mikulska M
Clin Microbiol Infect.2018 Mar 20 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (146view , 0users)

Full Text Sources

The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.
PMID: 29572070 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード